A study comparing knee OA patients who received AposHealth® against a control group found that AposHealth® patients did better in both patient-reported (subjective) clinical measures and functional test (objective) measures. Moreover, the AposHealth® group reported a significant reduction in painkiller consumption.

A controlled, double-blind study examined the effect of AposHealth® on the clinical results of subjects with knee OA. The study examined the changes in patient-reported outcome measures (PROMs) and in functional tests, among subjects who were assigned to AposHealth®, compared with a control group. 

AposHealth® was found to be superior regarding reduction in pain and improvement in function and quality of life. Furthermore, compared to the control group, subjects assigned to AposHealth® reported a reduction of over 50% in the consumption of over-the-counter painkillers.

Read the full text